UB Paderborn / Katalog / Suche / in CDI

1 – 16 von 16

Sortiert nach

Challenges in the Development and Reimbursement of Personalized Medicine—Payer and Manufacturer Perspectives and Implications for Health Economics and Outcomes Research: A Report of the ISPOR Personalized Medicine Special Interest Group

Value in health, 2012-12, Vol.15 (8), p.1162-1171

2012

Volltextzugriff (PDF)

Economic Evaluation of Everolimus versus Sorafenib for the Treatment of Metastatic Renal Cell Carcinoma after Failure of First-Line Sunitinib

Value in health, 2011-09, Vol.14 (6), p.846-851

2011

Volltextzugriff (PDF)

HOUT-18. COST EFFECTIVENESS OF TREATING GLIOBLASTOMA PATIENTS AGE 65 YEARS OR OLDER WITH TUMOR TREATING FIELDS PLUS TEMOZOLOMIDE VERSUS TEMOZOLOMIDE ALONE

Neuro-oncology (Charlottesville, Va.), 2018-11, Vol.20 (suppl_6), p.vi116-vi117

2018

Volltextzugriff (PDF)

Abstract LB-257: Tumor treating fields treatment for patients with newly diagnosed glioblastoma: A cost-effectiveness analysis

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.LB-257-LB-257

2018

Volltextzugriff (PDF)

Sustainability of Universal Health Coverage: Five Continents, Four Perspectives

Value in health, 2013, Vol.16

GARRISON, Lou

2013

Volltextzugriff (PDF)

HOUT-16. THE COST EFFECTIVENESS OF TUMOR TREATING FIELDS TREATMENT FOR PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA BASED ON THE EF-14 TRIAL

Neuro-oncology (Charlottesville, Va.), 2018-11, Vol.20 (suppl_6), p.vi116-vi116

2018

Volltextzugriff (PDF)

495 - Estimating the Current and Future Costs and Health Outcomes of Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HCT)

Transplantation and cellular therapy, 2023-02, Vol.29 (2), p.S371-S371

2023

Volltextzugriff (PDF)

Estimating the Current and Future Costs and Health Outcomes of Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HCT)

Transplantation and cellular therapy, 2023-02, Vol.29 (2), p.S371

2023

Volltextzugriff (PDF)

Extending the reach of public health genomics: What should be the agenda for public health in an era of genome-based and “personalized” medicine?

Genetics in medicine, 2010-12, Vol.12 (12), p.785-791

2010

Volltextzugriff (PDF)

What principles should govern the use of managed entry agreements?

International journal of technology assessment in health care, 2011-01, Vol.27 (1), p.77-83

2011

Volltextzugriff (PDF)

The Drug Budget Silo Mentality in Europe: An Overview

Value in health, 2003-07, Vol.6 (s1), p.S1-S9

2003

Volltextzugriff (PDF)

HOUT-18. COST EFFECTIVENESS OF TREATING GLIOBLASTOMA PATIENTS AGE 65 YEARS OR OLDER WITH TUMOR TREATING FIELDS PLUS TEMOZOLOMIDE VERSUS TEMOZOLOMIDE ALONE

Neuro-oncology (Charlottesville, Va.), 2018-11, Vol.20 (suppl_6), p.vi116-vi117

2018

Volltextzugriff (PDF)

A CORRELATIONAL STUDY OF FACTORS UTILIZED IN COUNSELOR CANDIDATE SELECTION AT WESTERN MICHIGAN UNIVERSITY

GARRISON, MARY LOU

1967

Volltextzugriff (PDF)

Characterization of serum antibody responses to recombinant HIV-1 gp160 vaccine by enzyme immunoassay

AIDS research and human retroviruses, 1990-11, Vol.6 (11), p.1251-1256

1990

Volltextzugriff (PDF)

Retention of Homeless Clients in Substance Abuse Treatment: Findings From the National Institute on Alcohol Abuse and Alcoholism Cooperative Agreement Program

Journal of substance abuse treatment, 1999-07, Vol.17 (1), p.45-66

1999

Volltextzugriff (PDF)

Retention of Homeless Clients in Substance Abuse Treatment

Journal of substance abuse treatment, 1999-07, Vol.17 (1-2), p.45-66

1999

Volltextzugriff (PDF)

1 – 16 von 16

Suche als RSS-Feed

Aktive Filter

Zeitschrift / SerieCancer Biotherapy & Radiopharmaceuticals

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(13)
Mit Volltextzugriff
(15)

Publikationsform

Sprache

Englisch
(16)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

3 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Challenges in the Development and Reimbursement of Personalized Medicine—Payer and Manufacturer Perspectives and Implications for Health Economics and Outcomes Research: A Report of the ISPOR Personalized Medicine Special Interest Group

Economic Evaluation of Everolimus versus Sorafenib for the Treatment of Metastatic Renal Cell Carcinoma after Failure of First-Line Sunitinib

HOUT-18. COST EFFECTIVENESS OF TREATING GLIOBLASTOMA PATIENTS AGE 65 YEARS OR OLDER WITH TUMOR TREATING FIELDS PLUS TEMOZOLOMIDE VERSUS TEMOZOLOMIDE ALONE

Abstract LB-257: Tumor treating fields treatment for patients with newly diagnosed glioblastoma: A cost-effectiveness analysis

Sustainability of Universal Health Coverage: Five Continents, Four Perspectives

HOUT-16. THE COST EFFECTIVENESS OF TUMOR TREATING FIELDS TREATMENT FOR PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA BASED ON THE EF-14 TRIAL

495 - Estimating the Current and Future Costs and Health Outcomes of Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HCT)

Estimating the Current and Future Costs and Health Outcomes of Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HCT)

Extending the reach of public health genomics: What should be the agenda for public health in an era of genome-based and “personalized” medicine?

What principles should govern the use of managed entry agreements?

The Drug Budget Silo Mentality in Europe: An Overview

HOUT-18. COST EFFECTIVENESS OF TREATING GLIOBLASTOMA PATIENTS AGE 65 YEARS OR OLDER WITH TUMOR TREATING FIELDS PLUS TEMOZOLOMIDE VERSUS TEMOZOLOMIDE ALONE

A CORRELATIONAL STUDY OF FACTORS UTILIZED IN COUNSELOR CANDIDATE SELECTION AT WESTERN MICHIGAN UNIVERSITY

Characterization of serum antibody responses to recombinant HIV-1 gp160 vaccine by enzyme immunoassay

Retention of Homeless Clients in Substance Abuse Treatment: Findings From the National Institute on Alcohol Abuse and Alcoholism Cooperative Agreement Program

Retention of Homeless Clients in Substance Abuse Treatment

Aktive Filter

Suchergebnisse filtern